Literature DB >> 21926236

Adenosine promotes alternative macrophage activation via A2A and A2B receptors.

Balázs Csóka1, Zsolt Selmeczy, Balázs Koscsó, Zoltán H Németh, Pál Pacher, Peter J Murray, Diane Kepka-Lenhart, Sidney M Morris, William C Gause, S Joseph Leibovich, György Haskó.   

Abstract

Adenosine has been implicated in suppressing the proinflammatory responses of classically activated macrophages induced by Th1 cytokines. Alternative macrophage activation is induced by the Th2 cytokines interleukin (IL)-4 and IL-13; however, the role of adenosine in governing alternative macrophage activation is unknown. We show here that adenosine treatment of IL-4- or IL-13-activated macrophages augments the expression of alternative macrophage markers arginase-1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and macrophage galactose-type C-type lectin-1. The stimulatory effect of adenosine required primarily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) increased both arginase activity (EC(50)=261.8 nM) and TIMP-1 production (EC(50)=80.67 nM), and both pharmacologic and genetic blockade of A(2B) receptors prevented the effect of NECA. A(2A) receptors also contributed to the adenosine augmentation of IL-4-induced TIMP-1 release, as both adenosine and NECA were less efficacious in augmenting TIMP-1 release by A(2A) receptor-deficient than control macrophages. Of the transcription factors known to drive alternative macrophage activation, CCAAT-enhancer-binding protein β was required, while cAMP response element-binding protein and signal transducer and activator of transcription 6 were dispensable in mediating the effect of adenosine. We propose that adenosine receptor activation suppresses inflammation and promotes tissue restitution, in part, by promoting alternative macrophage activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926236      PMCID: PMC3250237          DOI: 10.1096/fj.11-190934

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  57 in total

Review 1.  Other functions, other genes: alternative activation of antigen-presenting cells.

Authors:  S Goerdt; C E Orfanos
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

Review 2.  Alternatively activated macrophages during parasite infections.

Authors:  Wim Noël; Geert Raes; Gholamreza Hassanzadeh Ghassabeh; Patrick De Baetselier; Alain Beschin
Journal:  Trends Parasitol       Date:  2004-03

Review 3.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

4.  IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation.

Authors:  J Xaus; M Mirabet; J Lloberas; C Soler; C Lluis; R Franco; A Celada
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

Review 5.  Shaping of monocyte and macrophage function by adenosine receptors.

Authors:  György Haskó; Pál Pacher; Edwin A Deitch; E Sylvester Vizi
Journal:  Pharmacol Ther       Date:  2006-09-14       Impact factor: 12.310

Review 6.  Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.

Authors:  Jo A Van Ginderachter; Kiavash Movahedi; Gholamreza Hassanzadeh Ghassabeh; Sofie Meerschaut; Alain Beschin; Geert Raes; Patrick De Baetselier
Journal:  Immunobiology       Date:  2006-07-21       Impact factor: 3.144

7.  A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice.

Authors:  Bryan G Belikoff; Stephen Hatfield; Peter Georgiev; Akio Ohta; Dmitriy Lukashev; Jon A Buras; Daniel G Remick; Michail Sitkovsky
Journal:  J Immunol       Date:  2011-01-17       Impact factor: 5.422

8.  An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.

Authors:  Grace Pinhal-Enfield; Madhuri Ramanathan; Gyorgy Hasko; Stefanie N Vogel; Andrew L Salzman; Geert-Jan Boons; S Joseph Leibovich
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

9.  IL-4-dependent CD86 expression requires JAK/STAT6 activation and is negatively regulated by PKCdelta.

Authors:  Eric L Deszo; Danett K Brake; Keith W Kelley; Gregory G Freund
Journal:  Cell Signal       Date:  2004-02       Impact factor: 4.315

10.  The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells.

Authors:  Jeffrey M Wilson; William G Ross; Oma N Agbai; Renea Frazier; Robert A Figler; Jayson Rieger; Joel Linden; Peter B Ernst
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more
  149 in total

Review 1.  Regulation of tumor infiltrated innate immune cells by adenosine.

Authors:  Regina Strakhova; Octavia Cadassou; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2020-06-12       Impact factor: 3.765

2.  C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages.

Authors:  Donald M Lamkin; Shreyesi Srivastava; Karen P Bradshaw; Jenna E Betz; Kevin B Muy; Anna M Wiese; Shelby K Yee; Rebecca M Waggoner; Jesusa M G Arevalo; Alexander J Yoon; Kym F Faull; Erica K Sloan; Steve W Cole
Journal:  Brain Behav Immun       Date:  2019-05-24       Impact factor: 7.217

Review 3.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

4.  Ablation of Myeloid ADK (Adenosine Kinase) Epigenetically Suppresses Atherosclerosis in ApoE-/- (Apolipoprotein E Deficient) Mice.

Authors:  Min Zhang; Xianqiu Zeng; Qiuhua Yang; Jiean Xu; Zhiping Liu; Yaqi Zhou; Yapeng Cao; Xiaoyu Zhang; Xiaofei An; Yiming Xu; Lei Huang; Zhen Han; Tao Wang; Chaodong Wu; David J Fulton; Neal L Weintraub; Mei Hong; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

5.  G2A Protects Mice against Sepsis by Modulating Kupffer Cell Activation: Cooperativity with Adenosine Receptor 2b.

Authors:  Hong-Mei Li; Ji Hye Jang; Jun-Sub Jung; Jiseon Shin; Chul O Park; Yeon-Ja Kim; Won-Gyun Ahn; Ju-Suk Nam; Chang-Won Hong; Jongho Lee; Yu-Jin Jung; Jiang-Fan Chen; Katya Ravid; H Thomas Lee; Won-Ki Huh; Janusz H Kabarowski; Dong-Keun Song
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

6.  HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.

Authors:  Kemly Philip; Tingting Weng Mills; Jonathan Davies; Ning-Yuan Chen; Harry Karmouty-Quintana; Fayong Luo; Jose G Molina; Javier Amione-Guerra; Neeraj Sinha; Ashrith Guha; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2017-07-12       Impact factor: 5.191

Review 7.  Adenosinergic Signaling in Liver Fibrosis.

Authors:  Shilpa Tiwari-Heckler; Z Gordon Jiang
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-08-02

8.  Alternatively Activated Macrophages Revisited: New Insights into the Regulation of Immunity, Inflammation and Metabolic Function following Parasite Infection.

Authors:  Jessica C Jang; Meera G Nair
Journal:  Curr Immunol Rev       Date:  2013-08-01

9.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.

Authors:  David Vasquez-Dunddel; Fan Pan; Qi Zeng; Mikhail Gorbounov; Emilia Albesiano; Juan Fu; Richard L Blosser; Ada J Tam; Tullia Bruno; Hao Zhang; Drew Pardoll; Young Kim
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

10.  Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment.

Authors:  Laetitia Petit-Jentreau; Grégory Jouvion; Patricia Charles; Laleh Majlessi; Brigitte Gicquel; Ludovic Tailleux
Journal:  Infect Immun       Date:  2015-07-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.